Clinical Trial Update: A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Debio 1347 in combination with Fulvestrant for metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Debio 1347 (debio 1347)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-25